Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus.

CONCLUSIONS: Vildagliptin added to an ongoing metformin therapy allows to achieve better metabolic control parameters in comparison with a metformin monotherapy and the combination treatment is well tolerated and has a low risk of serious adverse effects. PMID: 25560571 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/25560571?dopt=Abstract

Source: Pharmacological Reports - January 11, 2015 Category: Drugs & Pharmacology Authors: Strózik A, Stęposz A, Basiak M, Drożdż M, Okopień B Tags: Pharmacol Rep Source Type: research